|
1）Redfield M. Heart Failure with Normal Ejection Fraction. In: Bonow R, et al, editors. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia: Elsevier; 2011. p.586-99
|
|
|
|
|
2）Tsuchihashi-Makaya M, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction-A report from the Japanese cardiac rejistry of heart failure in cardiology (JCARE-CARD). Circ J. 2009; 73: 1893-900
|
|
|
|
|
3）Rihal CS, Nishimura RA, Hatle LK, et al. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation. 1994; 90: 2772-9
|
|
|
|
|
|
4）Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities. J Card Fail. 2007; 13: 569-76
|
|
|
|
|
|
5）Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation. 2000; 102: 2269-75
|
|
|
|
|
|
6）Sakata Y, Masuyama T, Yamaoto K, et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol. 2001; 37: 293-9
|
|
|
|
|
|
7）van Heerebeek L, Borbely A, Niessen HWM, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006; 113: 1966-73
|
|
|
|
|
|
8）Masuyama T, Yamamoto K, Sakata T, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol. 2000; 36: 2333-8
|
|
|
|
|
|
9）Sakata Y, Yamamoto K, Mano T, et al. Angiotensin II type 1 receptor blockade prevents diastolic heart failure through modulation of Ca2＋ regulatory proteins and extracellular matrix. J Hypertens. 2003; 21: 1737-45
|
|
|
|
|
|
10）Yamamoto K, Masuyama T, Sakata Y, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res. 2002; 55: 76-82
|
|
|
|
|
|
11）Ohtani T, Ohta M, Yamamoto K, et al. Elevated cardiac tissue level of aldosterone and mineralo-corticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol. 2007; 292: 946-54
|
|
|
|
|
|
12）Ohtani T, Mano T, Hikoso S, et al. Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure. J Hypertens. 2009; 27: 1074-83
|
|
|
|
|
|
13）Rossier MF, Lenglet S, Vetterli L, et al. Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricu-lar cardiomyocytes. Hypertension. 2008; 52: 721-8
|
|
|
|
|
|
14）Manunta P, Stella P, Rivera R, et al. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hyper-tension. 1999; 34: 450-6
|
|
|
|
|
|
15）Kamimura D, Ohtani T, Sakata Y, et al. Ca2+ entry mode of Na+/Ca2+ exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J. 2012; 33: 1408-16
|
|
|
|
|
|
16）Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes LV remodeling in hypertensive heart failure rats; its inhibition as a primary effect of ACE inhibitor. Circulation. 2004; 109: 2143-9
|
|
|
|
|
|
17）Nishikawa N, Yamamoto K, Sakata Y, et al. Differential activation of matrix metalloprotei-nases in heart failure with and without ventri-cular dilation. Cardiovasc Res. 2003; 57: 766-74
|
|
|
|
|
|
18）Yamamoto K, Sakata Y, Ohtani T, et al. Heart failure with preserved ejection fraction. Circ J. 2009; 73: 404-10
|
|
|
|
|
|
19）Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation. 2005; 112: 2254-62
|
|
|
|
|
|
20）Borlaug BA, Paulus WJ. Heart failure with pre-served ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011; 32: 670-9
|
|
|
|
|
|
21）Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. J Cardiol. 2010; 55: 13-22
|
|
|
|
|
|
22）Kinugasa Y, Kato M, Sugihara S, et al. A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure--hypoalbuminemia as an additional prognostic factor. Circ J. 2009; 73: 2276-81
|
|
|
|
|
|
23）Arques S, Ambrosi P, Gelisse R, et al. Hypo-albuminemia in elderly patients with diastolic heart failure. J Am Coll Cardiol. 2003; 42: 712-6
|
|
|
|
|
|
24）Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011; 4: 324-31
|
|
|
|
|
|
25）Ishida K, Kato M, Kato y, et al. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest. 2009; 136: 125-9
|
|
|
|
|